loading page

Imlifidase Utilization in Glanzmann Thrombasthenia with Anti-GPIIb/IIIa and Anti-HLA Alloimmunization and Severe Platelet Refractoriness following Hematopoietic Stem Cell Transplant.
  • +6
  • Mohammad AlNajjar,
  • Ryan Rochat,
  • Amanda Grimes,
  • Amir Navaei,
  • Todd Eagar,
  • Caridad Martinez,
  • Khalid Yassine,
  • Robert Krance,
  • Saleh Bhar
Mohammad AlNajjar
Baylor College of Medicine Center for Cell and Gene Therapy
Author Profile
Ryan Rochat
Baylor College of Medicine Division of Pediatric Infectious Diseases
Author Profile
Amanda Grimes
Texas Children's Cancer Center and Hematology Centers
Author Profile
Amir Navaei
Baylor College of Medicine Texas Children's Hospital
Author Profile
Todd Eagar
Methodist Hospital
Author Profile
Caridad Martinez
Baylor College of Medicine Center for Cell and Gene Therapy
Author Profile
Khalid Yassine
Baylor College of Medicine Center for Cell and Gene Therapy
Author Profile
Robert Krance
Baylor College of Medicine Center for Cell and Gene Therapy
Author Profile
Saleh Bhar
Baylor College of Medicine Center for Cell and Gene Therapy

Corresponding Author:[email protected]

Author Profile

Abstract

Glanzmann Thrombasthenia (GT) is an inherited bleeding disorder of poor platelet function secondary to a defect in platelet membrane glycoprotein IIb/IIIa (GPIIb/IIIa). Patients with GT may develop anti-platelet antibodies including anti-GPIIb/IIIa which can lead to severe refractory thrombocytopenia and life-threatening bleeding, management of which is challenging. We report successful use of imlifidase, a novel IgG protease enzyme, as part of a multimodal approach for management of severe platelet refractoriness and alloimmunization in a child with GT and primary graft failure following hematopoietic stem cell transplant (HSCT). The patient had no detectable anti-platelet alloantibodies following imlifidase, and underwent a second HSCT.
08 Apr 2024Submission Checks Completed
08 Apr 2024Assigned to Editor
08 Apr 2024Submitted to Pediatric Blood & Cancer
10 Apr 2024Review(s) Completed, Editorial Evaluation Pending
20 Apr 2024Reviewer(s) Assigned
11 Jul 2024Submission Checks Completed
11 Jul 2024Assigned to Editor
11 Jul 20241st Revision Received
12 Jul 2024Review(s) Completed, Editorial Evaluation Pending
18 Jul 2024Reviewer(s) Assigned
14 Aug 2024Editorial Decision: Revise Minor
13 Sep 20242nd Revision Received
13 Sep 2024Submission Checks Completed
13 Sep 2024Assigned to Editor
14 Sep 2024Review(s) Completed, Editorial Evaluation Pending
19 Sep 2024Reviewer(s) Assigned
14 Oct 2024Editorial Decision: Accept